Plain language summary {#S0001}
======================

Surgical site infection is the leading cause of unplanned and potentially preventable hospital readmission in surgical patients. Prescribing antibiotics before surgery is a well-proved approach to reduce the infection risk in patients underwent surgery. But, overuse of these drugs is observed in many hospitals of developing countries which increases the risk of drug resistance and imposes financial burden on patients and hospitals. Therefore, implementation of standard protocols can overcome these challenges. In this study, we designed a program including revising the institutional protocol, assigning a clinical pharmacist to the surgical department, and arranging several meetings with surgical department regarding the appropriate utilization of antibiotics. We surveyed different parameters before and after the designed program such as incidence and rate of infection, choice of prophylactic drugs, duration of drugs use, length of hospital stay, and financial costs. We found that the quality improvement project and implementation of protocol significantly improved rational use of antibiotics among gastrointestinal surgeons and residents as well as reduced drug usage costs and length of hospital stay.

Introduction {#S0002}
============

Surgical site infection (SSI) is the leading cause of unplanned and potentially preventable hospital readmission in surgical patients.[@CIT0001],[@CIT0002] It is considerably involved in surgery-related morbidity and increased health-care costs.[@CIT0003] Depending on the operative site and degree of contamination, SSIs occur in up to 10% of surgeries.[@CIT0004] However, this rate can vary between populations. For instance, it has been reported that there is an adverse relationship between the SSI rate and Human Development Index (HDI). The SSI rate in high-HDI countries is 9.4%, while these rates in the middle-HDI and low-HDI countries are 14.0% and 23.2%, respectively.[@CIT0005] According to a report, the incidence of health care--associated infections (HAIs) in Iran is 1.18, with 14.6% SSIs.[@CIT0006]

The Iranian Center for Communicable Disease Control is responsible for monitoring HAIs in Iran.[@CIT0007] As mentioned, SSIs comprise a remarkable share of HAIs in Iran.[@CIT0006] Because of the devastating complications of SSIs, a great number of attempts have been made to prevent or reduce this surgical complication. Surgical antibiotic prophylaxis (SAP) has become an accepted part of surgical practice to prevent infections at the surgical site and optimize postoperative recovery.[@CIT0008] The efficiency of AP in inhibiting operative infections has been confirmed in numerous investigations. It has been well proven that infection incidence in surgical patients with no AP is significantly higher than those receiving prophylactic antibiotics.[@CIT0009],[@CIT0010]

The guidelines were introduced to provide practitioners with a standardized approach to the safe and effective use of antibiotic drugs for the prevention of SSIs, based on currently available clinical indications and emerging issues.[@CIT0009] During the last few decades, several papers have been published on optimal AP, and in this regard international guidelines for surgical prophylaxis have been updated and propagated.[@CIT0011] Despite this, studies have shown that optimal practice is not achieved in many hospitals, especially in developing countries.[@CIT0012],[@CIT0013] The knowledge and attitudes of surgeons about appropriate SAP are important factors in the implementation of guidelines. It is necessary for hospital administrators and institutional quality-improvement departments to provide approaches to reduce such outcomes of antibiotic overuse as increased antibiotic resistance and higher financial costs to hospitals. To address this gap, we designed this study to determine the efficacy of adherence to SAP guidelines clinically and economically.

Methods {#S0003}
=======

Setting and data collection {#S0003-S2001}
---------------------------

Patients admitted to the gastrointestinal surgical ward of Shahid Faghihi Hospital of Shiraz University, which is a high-volume tertiary teaching hospital, were included in this study. This was a prospective cross-sectional study conducted from October 2017 to June 2018 (Effective Practice and Organisation of Care taxonomy: implementation strategies \[category\]/authority and accountability for quality of practice \[subcategory\]) performed in two phases: phase 1 between October 2017 and January 2017 (pre intervention group) and phase 2 between March 2018 and June 2018 (postintervention group). Patients were included if they had undergone gastrointestinal surgery ([Table 1](#T0001){ref-type="table"}). Exclusion criteria were patients who had received therapeutic antibiotics to treat bacterial infections prior to the intervention procedure or who had symptoms of infection after the intervention procedure and if they declined to provide informed consent. The study was in accordance with the Declaration of Helsinki (1975) and local regulations. It was also approved by the ethical committee of the Shiraz University of Medical Sciences (94-01-05-10183). Written consent was obtained from all study participants or their legal guardians.Table 1Summary of Infectious Diseases Society of America guideline recommendations for antimicrobial prophylaxis in adultsGuideline (AP for GI surgery)Antibiotic choiceUsual doseGastric/duodenal/esophageal (eg, bypass, resection, esophagectomy)Cefazolin2 g IV (single dose) bolus over 5 minutesHernia repair (with mesh insert)Cefazolin2 g IV (single dose) bolus over5 minutes, repeat if operation duration \>4 hoursColorectal (eg, colon or small-bowel resection, obstruction, revision of anastomosis or stoma, appendectomy)\*Cefazolin + \*\*metronidazole\*2 g IV (single dose) bolus over 5 minutes or ceftriaxone 2 g (single dose)\
\*\*500 mg IV (single dose) infused over 20 minutesExploratory laparotomy/division of adhesions\*Cefazolin + \*\*metronidazole\*2 g IV (single dose) bolus over 5 minutes\
\*\*500 mg IV (single dose) infused over 20 minutesBiliary (open surgery or high-risk laparoscopic cholecystectomy)Cefazolin2 g IV (single dose) bolus over 5 minutesCeftriaxone2 g IV (single dose)Pancreatic resection\*Cefazolin + \*\*metronidazole\*2 g IV (single dose) bolus over 5 minutes\
\*\*500 mg IV (single dose) infused over 20 minutesSplenectomy vaccination and postsplenectomy antibiotic prophylaxis may be required\
Contact infection controlCefazolin2 g IV (single dose) bolus over 5 minutes before incisionEndoscopy retrograde cholangiopancreatography with expected incomplete drainage (eg, primary sclerosing cholangitis, biliary stricture)Cefazolin2 g IV (single dose) bolus over 5 minutesPiperacillin/tazobactam4.5 g IV (single dose) infused over 30 minutes before procedurePercutaneous endoscopic gastrostomy or percutaneous endoscopic jejunostomy insertionCefazolin2 g IV (single dose) bolus over 5 minutes before incisionAny endoscopic or colonoscopy procedure for endocarditis or prosthetic joint-infection prophylaxisNot recommendedSclerotherapy, esophageal dilationNot recommendedRisk, laparoscopic biliary systemNot recommendedUncomplicated appendectomy\*Cefazolin + \*\*metronidazole\*2 g IV (single dose) bolus over 5 minutes, repeat if operation duration \>4 h\
\*\*500 mg IV (single dose)[^1][^2]

Study description {#S0003-S2002}
-----------------

The criteria of prophylactic antibiotic--usage evaluation were established based on the guidelines developed jointly by the American Society of Health-System Pharmacists, Infectious Diseases Society of America (IDSA), Surgical Infection Society, and Society for Healthcare Epidemiology of America ([Table 1](#T0001){ref-type="table"}).[@CIT0014] Before the intervention period, a project consisting of revising the institutional guidelines for surgical antimicrobial prophylaxis based on the aforementioned guidelines, assigning a clinical pharmacist to the surgical department and arranging several meetings with the surgical department on the appropriate utilization of antibiotics, was developed in February 2018. Senior clinical pharmacists trained in infectious diseases would deliver lectures about SAP to key members of surgical departments.

Interventions consist of participating in ward rounds, attending recovery rooms, and making drug-treatment plans, and communicating immediately with surgeons in cases of discordance with guidelines. Educational sessions and handouts containing an abstract and general tips on SAP guidelines about AP for medical teams, especially surgical residents, were provided.

In each stage, data on the characteristics of the surgical patients were collected and the rationality of SAP during the perioperative period was evaluated according to the established criteria ([Table 1](#T0001){ref-type="table"}). Data on irrational SAP were collected and evaluated by clinical pharmacists. In the pre intervention phase, discordance with the guidelines was recorded, but in the second phase (postintervention) clinical pharmacists communicated with the doctors responsible for order entry directly for correction of unreasonable cases and advice on rationality of the prescription.

Medical records of included patients, such as surgery characteristics and SAP (agent type, doses, dose intervals, number of doses, administration duration, and cost) were reviewed and recorded. SSIs were defined by the US Centers for Disease Control and Prevention definitions for surgical site--infection surveillance.[@CIT0011] At the end of the intervention period, an infection-control nurse who was blinded to patient group recorded the clinical data of patients in both groups.

Identification of SSI cases {#S0003-S2003}
---------------------------

Early SSI diagnosis was performed using clinical observation by surgeons. In the laboratory, different blood parameters, such as white blood--cell count, erythrocyte-sedimentation rate, and CRP, were assessed in patients suspected of infection. Then, patient samples, such as blood and wound-discharge samples, were evaluated using various microbial-culture techniques to confirm SSIs.

Statistical analysis {#S0003-S2004}
--------------------

Data were analyzed using SPSS 19.0 (SPSS). Comparisons between the groups were made on patient characteristics, incidence and rate of infection, choice of prophylaxis antibiotics, duration of prophylaxis-antibiotic use, length of hospitalization, and financial costs. Analyses were conducted using Student's *t*-test for continuous variables. As some continuous variables for data were not normally distributed, Mann--Whitney *U* tests were used to evaluate the statistical significance of between-group differences. Rates were analyzed by comparison of proportions with Pearson *χ*^2^. *P*≤0.05 was considered statistically significant.

Results {#S0004}
=======

Data assessment {#S0004-S2001}
---------------

We recorded 875 patients who were admitted to the gastrointestinal surgery department during the 8 months of the study period. Patient characteristics are shown in [Table 2](#T0002){ref-type="table"}. Both groups were similar with respect to demographics and clinical characteristics ([Table 1](#T0001){ref-type="table"}). The most frequently used prophylaxis antibiotic in the pre intervention group and postintervention group was cefazolin sodium and metronidazole, respectively. The distribution of antibiotics used in our study is shown in [Table 3](#T0003){ref-type="table"}. There was a significant decrease in the proportion of patients who underwent inappropriate AP in the intervention phase (91.40%) compared with the baseline phase (30.11%; *P*\<0.001; [Table 2](#T0002){ref-type="table"}). Likewise, there was a significant increase in the proportion of patients receiving AP for no more than 48 hours (*P*\<0.01). The most frequently reported type of discordance with the guidelines in the pre intervention group was longer duration of antibiotic usage than guideline recommendations (*P*\<0.001).Table 2Patient characteristicsGroup 1\*Group 2\*\**P*-valueAge (years) mean (SD)51.06 (12.60%)51.58 (13.14%)0.44Sex,\
n (%)Female207 (46.52%)234 (54.42%)0.232Male238 (53.48%)196 (45.58%)Surgical type,\
n (%)Biliary38 (8.54%)6 (1.40%)0.19Colorectal318 (71.46%)338 (78.60%)Exploratory laparotomy38 (8.54%)43 (10.00%)Gastrectomy19 (4.27%)18 (4.19%)Hernia repair25 (5.62%)21 (4.88%)Splenectomy7 (1.57%)4 (0.93%)Serum creatinine (SD)0.98 (0.30%)0.99 (0.24%)0.81[^3] Table 3Rationality of prophylactic-antibiotic selectionGroup 1\*, n (%)Group2\*\*, n (%)*P*-valueTiming0--48 hours35 (7.87%)405 (94.19%)\<0.001\>48 hours121 (92.14%)25 (5.71%)SelectionCeftriaxone156 (35.06%)74 (17.21%)0Ciprofloxacin3 (0.67%)0Metronidazole203 (45.62%)92 (21.40%)Cefazolin16 (3.60%)264 (61.39%)Vancomycin19 (4.27%)0Imipenem27 (6.07%)0Clindamycin3 (0.67%)0Meropenem3 (0.67%)0Ampibactam12 (2.70%)0Teicoplanin3 (0.67%)0Appropriateness134 (30.11%)393 (91.40%)\<0.001[^4]

Clinical and economic outcomes {#S0004-S2002}
------------------------------

To evaluate clinical impact, we assessed influences of intervention on the length of hospital stay in both groups. There was a significant decrease in length of hospital stay in the postintervention group (4.33 days) compared with the pre intervention group (5.14 days). A significant decrease was also noted in the SSI rate in the intervention group compared to the baseline group (*P*=0.01). The mean cost of AP for patients in the baseline and intervention groups was US\$647 and \$56, respectively (*P*\<0.001) between two groups. In the pre intervention group, the mean cost of the antibiotic prescriptions was 11.5 times greater than the case group ([Table 4](#T0004){ref-type="table"}). There were no changes in the prices of antibiotics during the two phases.Table 4Clinical and economic outcomes before and after interventionPre interventionPost intervention*P*-valueMean prophylactic-antibiotic cost (US\$), mean (SD)647 (20.80)56 (1.80)\<0.001Length of hospitalization, days, (SD)5.14 (2.42)4.33 (1.04)\<0.001Rate of surgical site infection, n (%)30 (6.74)13 (3.02)0.01

Discussion {#S0005}
==========

Wth the aim of reducing the incidence of SSI, SAP is an adjunct to surgical procedures. To our knowledge, this is the first interventional study for gastrointestinal surgery focusing on clinical and economical impact of IDSA-guideline implementation in Iran. In this study, guideline implementation by clinical pharmacist intervention led to a significant improvement in prophylactic-antibiotic prescription, with favorable economic and clinical outcomes. These favorable results were achieved via correction of antibiotic choices, their timing of preoperative administration, and proper duration of AP, while unnecessary prescriptions and inappropriate combinations were decreased. Also, our intervention resulted in shortened length of hospital stay and decreased medication cost and SSI rate. This study revealed poor adherence to the prophylaxis guidelines in the pre intervention phase. This lack of adherence was attributed mainly to the absence of comprehensive institutional guidelines, easy accessibility to several antibiotics that were not included in the guidelines, and the preference of surgeons to overuse antimicrobial prophylactic drugs to decrease the risk of infection. Similar findings have been reported by other studies.[@CIT0015]--[@CIT0017]

During the intervention phase, patients received optimized antibiotic prescriptions, with a significant mean cost reduction of \$591. A major reason for this cost reduction was a significant decrease in the duration of antibiotic use in the intervention group (94.19%) compared to the baseline group (7.87%; *P*\<0.001). In Iran, the government provides most of the financial resources needed for the health-care system. Despite the fact that most generic drugs, including antibiotics, are produced in Iran, the extended use of these drugs imposes a huge financial burden on the Ministry of Health.[@CIT0018] Therefore, adherence to prophylaxis guidelines can avoid any unnecessary costs in this context.

Research has revealed that prolongation of AP after surgery is not necessary. In fact, the extended use of antibiotics increases the risk of antibiotic resistance and imposes a financial burden on patients and hospitals.[@CIT0019] However, prolongation of AP, as was seen in the pre intervention group of this study, continues to be the main point of noncompliance with guidelines in surgery wards. Several published guidelines suggest that a single dose of cefazolin is sufficient for preventing SSIs in most gastrointestinal surgeries.[@CIT0020] A meta-analysis performed by Shen et al[@CIT0021] did not find any additional advantage for postoperative maintenance antibiotics. Another study has shown that prolonged antibiotic use increases the risk of resistant strains without any advantage.[@CIT0022] Similarly, in our report, prolongation of antibiotic administration was not associated with any decrease in SSI rate in the pre intervention group, and interestingly this rate was higher than the post intervention group. Emerging drug-resistant strains due to prolonged antibiotic usage are a possible reason for this phenomenon. Another reason could be improvement in knowledge about infection control when the surgery team are involved in teaching sessions about SAP and they are aware that their practice is observed by another authority. However, more studies are needed to clarify how adherence to the guidelines diminishes the SSI rate compared to antibiotic overuse.

Ideally, a guideline for surgical prophylaxis should stop SSIs, stop SSI-related morbidity and mortality, reduce the duration of health care and related financial cost,[@CIT0023],[@CIT0024] and generate no adverse effects.[@CIT0025] Over the past few decades, several organizations, hospitals, and government agencies, including the IDSA, have established national quality-improvement initiatives to further improve the safety and outcomes of surgery.[@CIT0014] One aspect of focus in these initiatives for patients undergoing surgery is the prevention of SSIs. According to studies in US hospitals, application of updated international guidelines, such as those of the IDSA, is an efficient, sensitive, and reliable method of surveillance of antimicrobial prophylaxis.[@CIT0026] At the same time, similar guidelines have been revealed to be of value and are now established in several hospitals in some European countries.[@CIT0027]

The implementation of institutional guidelines for SSI prophylaxis plays a crucial role in guiding surgeons to use the most appropriate antibiotics and doses based on evidence-based recommendations. These guidelines should be tailored to the needs of each institution, based on the pattern of antimicrobial resistance, most common types of surgeries performed, and the antibiotics available. In 2004, a multicenter prospective Japanese study assessed the efficacy of a protocol of prophylactic-antibiotic use to prevent SSIs in urological surgery. The results of this study showed that using protocols efficiently decreased the amount of antibiotics used and consequently financial cost without increasing infection rates.[@CIT0028] Another study conducted by Trinchieri et al[@CIT0029] was designed to evaluate incidence of SSIs in a urology ward after application of the European Association of Urology guidelines. They concluded that antimicrobial prophylaxis according to the association\'s guidelines seemed to be adequate to prevent symptomatic/febrile genitourinary infections. Additional cost savings might be realized through collaborative management by surgeons and clinical pharmacists to choose the most cost-effective drug and reduce or eliminate postoperative dosing.[@CIT0030],[@CIT0031] In addition, the application of standardized antibiotic order sets, automatic stop-order programs, and educational courses has been also shown to facilitate the adoption of updated guidelines for surgical antimicrobial prophylaxis.[@CIT0032]--[@CIT0036]

A significant improvement in adherence to antimicrobial-prophylaxis guidelines was noted in the current study after implementation of a quality-improvement project. The provision of educational sessions and assignment of a clinical pharmacist in a surgery department clearly played a major role in the improved compliance. In the current study, the authors believe that the presence of a clinical pharmacist in a surgical department was essential in encouraging adherence to the revised antimicrobial-prophylaxis guidelines. This clinical pharmacist helped with specific recommendations related to prescribing antibiotics for surgical residents. It is necessary to implement local guidelines and continuous audit and feedback to surgeons regarding the appropriateness of their practice to achieve sustained clinical and economic improvement in prophylactic-antibiotic usage.

Several limitations of this study should be acknowledged. First of all, it had pre- vs post intervention design. This prospective study was less convincing than a randomized controlled trial. Second, our study was done in 8 months. We did not evaluate the sustained effects of guideline implementation after the interventions had finished. Future studies are recommended to explore duration of adherence to antimicrobial-prophylaxis guidelines.

Conclusion {#S0006}
==========

In the present study, IDSA-guideline implementation through a quality-improvement project significantly improved the rational use of AP among gastrointestinal surgeons and residents and reduced antibiotic-usage costs and length of hospitalization. It is essential for surgeons to be aware of the importance of adherence to AP guidelines and to know that this adherence has a positive impact on patient outcomes. The results of our study emphasize that clinical pharmacists can help to enhance adherence to institutional antimicrobial-prophylaxis guidelines and decrease irrational drug utilization.
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[^1]: **Notes:** At the end of the intervention period, an infection-control specialist who was blinded to patient group recorded clinical data of patients in both groups. A Microsoft Excel table was designed to register type of surgical procedure, pharmacotherapy received, antibiotic usage (generic name, doses, dose intervals, and durations of administration), and costs (costs of hospitalization and antibiotics).

[^2]: **Abbreviations:** AP, antimicrobial prophylaxis; GI, gastrointestinal; IV, intravenous.

[^3]: **Notes:** \*Before Intervention; \*\*after intervention.

[^4]: **Notes:** *\**Preintervention group; \*\*postintervention group.
